Regioselective radiofluorodestannylation with [18F]F2 and [18F]CH3COOF: a high yield synthesis of 6-[18F]Fluoro-L-dopa.

A protected 6-trimethylstannyl dopa derivative 6 has been synthesized for the first time as a precursor for the preparation of 6-[18F]fluoro-L-dopa. The tin derivative 6 readily reacted with electrophilic radiofluorinating agents such as [18F]F2 and [18F]AcOF. The [18F]fluoro intermediate 7 was easily hydrolyzed with HBr and the product 6-[18F]fluoro-L-dopa was isolated after HPLC purification in a maximum radiochemical yield of 25%, ready for human use. The various intermediates, the stannyl precursor 6 and the final product (after 18F decay) were all fully characterized by 1H, 13C, 19F and 119Sn NMR as well as high resolution mass spectroscopy.

[1]  C. Eaborn,et al.  Synthesis of organotrialkylstannanes. The reaction between organic halides and hexaalkyldistannanes in the presence of palladium complexes , 1981 .

[2]  Michael E. Phelps,et al.  Remote, semiautomated production of 6-[18F]fluoro-L-dopa for human studies with PET. , 1990 .

[3]  B. Pate,et al.  Routine synthesis of L-[18F]6-fluorodopa with fluorine-18 acetyl hypofluorite. , 1986, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[4]  Mariana Adam,et al.  Synthesis and purification of ?-6-[18F]fluorodopa , 1988 .

[5]  J. Barrio,et al.  The synthesis of 2-[F-18]fluoro-2-deoxy-D-glucose using glycals: a reexamination. , 1984, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[6]  C. D. Schaeffer,et al.  Tin-119 chemical shifts of ortho, meta, para, 2,6-, and polysubstituted aryltrimethyltin derivatives and related organotin compounds , 1975 .

[7]  C. D. Schaeffer,et al.  Pulsed fourier transform NMR of substituted aryltrimethyltin derivatives : II. (119Sn-13C) coupling constants and 13C chemical shifts of meta- and para-derivatives , 1973 .

[8]  R. Chirakal,et al.  Aromatic radiofluorination with [18F]fluorine gas: 6-[18F]fluoro-L-dopa. , 1984, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[9]  C. Nahmias,et al.  Dopamine visualized in the basal ganglia of living man , 1983, Nature.

[10]  R. Silverstein,et al.  Spectrometric identification of organic compounds , 2013 .

[11]  C. Lemaire,et al.  No-carrier-added regioselective preparation of 6-[18F]fluoro-L-dopa. , 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[12]  L. Hall,et al.  The cleavage of aryl-metal bonds by elemental fluorine: synthesis of aryl-fluorides' , 1983 .

[13]  J. Grierson,et al.  Reaction of [18F]acetyl hypofluorite with derivatives of dihydroxyphenylalanine: Synthesis of l-[18F]6-fluorodopa , 1986 .

[14]  B. Pate,et al.  Fluorination of aromatic compounds with F2 and acetyl hypofluorite: synthesis of 18F-aryl fluorides by cleavage of aryl-tin bonds [1] , 1984 .

[15]  H. H. Coenen,et al.  Regiospecific aromatic fluorodemetallation of group IVb metalloarenes using elemental fluorine or acetyl hypofluorite , 1987 .

[16]  H. Atkins,et al.  Radiopharmaceuticals. 16. Halogenated dopamine analogs. Synthesis and radiolabeling of 6-iododopamine and tissue distribution studies in animals. , 1976, Journal of medicinal chemistry.

[17]  D. Doddrell,et al.  Carbon-13 Nuclear Magnetic Resonance Studies of Benzocycloalkenes and Fluorobenzocycloalkenes , 1976 .

[18]  C. Lemaire,et al.  An approach to the asymmetric synthesis of l-6-[18F]fluorodopa via NCA nucleophilic fluorination☆ , 1991 .

[19]  M. Diksic,et al.  New synthesis of fluorine-18-labeled 6-fluoro-L-dopa by cleaving the carbon-silicon bond with fluorine. , 1985, Journal of Nuclear Medicine.

[20]  J. Hartwell,et al.  The Absolute Configuration of Lignans2 , 1957 .

[21]  A. Luxen,et al.  Fluorination of substituted veratroles via regioselective mercuration , 1988 .

[22]  T. Chaly,et al.  High yield synthesis of 6-[18F]fluoro-L-dopa by regioselective fluorination of protected L-dopa with [18F]acetylhypofluorite. , 1986, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.